Meizhong Xu

This inventor holds 40 USPTO granted patents and 11 published patent applications, plus 9 CIPO patents and 16 EPO patents, primarily in Kinase Inhibitors. Top assignees: Incyte Corporation, Incyte Holdings Corporation. Active years: 2007-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Meizhong Xu. Retrieved from https://idiyas.com/inventor/meizhong-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 11)

% Patents Active = 90.0

CIPO Patents = 9 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 6.3

ph-index = 18

Forward Citations = 586(Granted Patents)

Location History:

Hockessin, DE (2015)
Hockessin, DE (US) (2007 - 2024)

Company Filing History:

Incyte Holdings Corporation

patents

where one patent can have more than one assignee

Years Active: 2007-2025

Loading Chart...

Areas of Expertise:

CDK2 Inhibitors

FGFR Inhibitors

Metalloprotease Inhibitors

Immunomodulators

Heterocyclic Compounds

Aza Spiro Alkane Derivatives

Triazolotriazines

Lactam Compounds

Amido Compounds

Imidazopyridines

Pyrazolyl Compounds

Bicyclic Amines

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12466828 - BICYCLIC AMINES AS CDK2 INHIBITORS (2025-11-11),

2. 12084449 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2024-09-10),

3. 11566026 - Heterocyclic compounds as immunomodulators (2023-01-31),

4. 11472791 - Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors (2022-10-18),

5. 11261191 - Imidazotriaines and imidazopyrimidines as kinase inhibitors (2022-03-01),

6. 10947230 - Bicyclic heterocycles as FGFR inhibitors (2021-03-16),

7. 10813930 - Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 (2020-10-27),

8. 10793565 - Heterocyclic compounds as immunomodulators (2020-10-06),

9. 10738052 - Imidazotriaines and imidazopyrimidines as kinase inhibitors (2020-08-11),

10. 10640503 - Imidazopyridines and imidazopyrazines as LSD1 inhibitors (2020-05-05),

11. 10226459 - Aza spiro alkane derivatives as inhibitors of metalloproteases (2019-03-12),

12. 10213427 - Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 (2019-02-26),

13. 10047086 - Imidazopyridines and imidazopyrazines as LSD1 inhibitors (2018-08-14),

14. 9957229 - Amido compounds and their use as pharmaceuticals (2018-05-01),

15. 9944645 - Imidazotriazines and imidazopyrimidines as kinase inhibitors (2018-04-17),

Title: Meizhong Xu: Pioneering Inventor from Hockessin

Introduction: Meizhong Xu is a distinguished inventor hailing from Hockessin, Delaware. His innovative spirit and dedication to technological advancements have made him a prominent figure in the world of patents and inventions.

Latest Patents: Meizhong Xu holds several groundbreaking patents in various fields, including technology, engineering, and healthcare. His recent patents focus on sustainable energy solutions and cutting-edge medical devices, showcasing his versatility and forward-thinking approach.

Career Highlights: With a career spanning over two decades, Meizhong Xu has consistently pushed the boundaries of innovation. His work has not only revolutionized existing industries but has also paved the way for new opportunities and advancements in the field of technology.

Collaborations: Meizhong Xu has collaborated with leading research institutions, universities, and companies to bring his inventions to life. His partnerships have been instrumental in turning his visionary ideas into tangible products that have a positive impact on society.

Conclusion: Meizhong Xu's passion for innovation, coupled with his relentless drive to create a better future through technology, sets him apart as a true trailblazer in the world of inventions. His contributions continue to inspire the next generation of inventors and shape the landscape of innovation for years to come.

Profile summary based on public USPTO records.